TNFRSF10A: Tumor necrosis factor receptor superfamily member 10A
Receptor for the cytotoxic ligand TNFSF10/TRAIL.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on TNFRSF10A, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
- Protein or peptide 1
| Dulanermin | Phase 2 | Roche | Protein or peptide | AgonistTRAIL receptor-1 agonist | 0 |
| Mapatumumab | Phase 2 | GSK | Antibody | AgonistTRAIL receptor-1 agonist | 0 |
- Age-related macular degeneration0.57
- Neurodegenerative disease0.54
- COVID-190.44
- Central serous retinopathy0.37
- Wet macular degeneration0.36
- Atrophic macular degeneration0.36
- Respiratory insufficiency0.23
- Endometriosis0.22
- Non-small cell lung carcinoma0.13
- Neoplasm0.12
- Colorectal carcinoma0.10
- Miyoshi myopathy0.10
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3551, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt O00220, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets